Description: Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, Beifushu eye gel, and Beifushu unit-dose eye drops; Tobramycin eye drops, Levofloxacin eye drops, and Sodium Hyaluronate eye drops, as well as Iodized Lecithin Capsules. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels for use in burn and scald wounds, acute wounds, surgical incisions, chronic wounds, skin grafting, and other applications. In addition, it offers ophthalmic and surgical products from third parties. Further, the company offers Carisolv dental caries removal gel; and Yi Xue An Granules. It has license agreements with Mitotech S.A. and Mitotech LLC. The company was founded in 1990 and is headquartered in Zhuhai, China.
Home Page: www.essexbio.com
No. 88 Keji 6th Road
Zhuhai,
China
Phone:
86 75 6391 1188
Officers
| Name | Title |
|---|---|
| Dr. Mia Je Ngiam B.Sc. | Founder & Chairman |
| Mr. Haizhou Fang | MD & Exec. Director |
| Mr. Hian Leng Ngiam | Exec. Director & Deputy MD |
| Ms. Lai Man Yau A.C.A., ACA, C.P.A., CPA, M.B.A., MBA | Exec. Director & Company Sec. |
| Dr. Qi Xue | Group Chief Scientific Officer |
Exchange: HK
Country: HK : Hong Kong
Currency: Hong Kong Dollar (HK$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 7.4815 |
| Price-to-Book MRQ: | 1.3447 |
| Price-to-Sales TTM: | 1.5391 |
| IPO Date: | 2001-06-27 |
| Fiscal Year End: | December |
| Full Time Employees: | 1423 |